Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | AOC2 | O75106 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10567818 | 0.84 | CYP2D6 (0.47) | KDM4ECYP2D6 | |
| SCHEMBL11135476 | 0.80 | ALDH1A1 (0.42) | SMN1; SMN2KEAP1KDM4ECYP2D6ALDH1A1 | |
| SCHEMBL2783147 | 0.79 | CYP2D6 (0.43) | KDM4ECYP2D6 | |
| SCHEMBL12017298 | 0.79 | SMN1; SMN2 (0.36) | SMN1; SMN2KEAP1KDM4ECYP2D6ALDH1A1 | |
| SCHEMBL5858944 | 0.78 | KDM4E (0.43) | SMN1; SMN2KEAP1KDM4EALDH1A1RECQL | |
| SCHEMBL11483109 | 0.78 | SMN1; SMN2 (0.37) | SMN1; SMN2KEAP1KDM4ECYP2D6ALDH1A1 | |
| SCHEMBL5858941 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2KEAP1KDM4EALDH1A1RECQL | |
| SCHEMBL862113 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2KEAP1KDM4ECYP2D6ALDH1A1 | |
| SCHEMBL11972631 | 0.77 | CYP2D6 (0.41) | SMN1; SMN2KDM4ECYP2D6ALDH1A1SIGMAR1 | |
| SCHEMBL3983973 | 0.77 | CYP2D6 (0.41) | SMN1; SMN2KDM4ECYP2D6ALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1549613-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | Abbott Laboratories (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | SMN1; SMN2 1949/4885KEAP1 3133/4885KDM4E 2363/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | SMN1; SMN2 1949/4885KEAP1 3133/4885KDM4E 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.